Journal article
Abstract 212: Andexanet Alfa, a Universal Antidote for Reversal of Anticoagulation of Factor Xa Inhibitors in Healthy Human Volunteers
Abstract
Introduction: Andexanet alfa (AnXa) is a recombinant modified fXa molecule that acts as a specific antidote for fXa inhibitors. We report clinical results in healthy subjects anticoagulated with apixaban (apix), rivaroxaban (riva), edoxaban (edox), or enoxaparin (enox), demonstrating rapid and sustained reversal of anticoagulation following administration of AnXa. Methods: These were Phase 2/3 randomized, double-blind, placebo-controlled …
Authors
Crowther M; Gold AM; Lu G; Leeds JM; Wiens BL; Mathur V; Castillo J; Conely PB; Connolly SJ; Curnutte JT
Journal
Stroke, Vol. 47, No. suppl_1,
Publisher
Wolters Kluwer
Publication Date
February 2016
DOI
10.1161/str.47.suppl_1.212
ISSN
0039-2499